190 related articles for article (PubMed ID: 35217990)
1. Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer.
Feng J; Lu H; Ma W; Tian W; Lu Z; Yang H; Cai Y; Cai P; Sun Y; Zhou Z; Feng J; Deng J; Shu Y; Qu K; Jia W; Gao P; Zhang H
Protein Cell; 2022 Nov; 13(11):825-841. PubMed ID: 35217990
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.
Sun W; He B; Yang B; Hu W; Cheng S; Xiao H; Yang Z; Wen X; Zhou L; Xie H; Shen X; Wu J; Zheng S
Lab Invest; 2018 Jun; 98(6):734-744. PubMed ID: 29467456
[TBL] [Abstract][Full Text] [Related]
3. Interference with circRNA DOCK1 inhibits hepatocellular carcinoma cell proliferation, invasion and migration by regulating the miR-654-5p/SMAD2 axis.
Lu Y; Zhang J; Wu Y
Mol Med Rep; 2021 Aug; 24(2):. PubMed ID: 34184075
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of AMPK activation and therapeutic effects of metformin in hepatocellular carcinoma.
Zheng L; Yang W; Wu F; Wang C; Yu L; Tang L; Qiu B; Li Y; Guo L; Wu M; Feng G; Zou D; Wang H
Clin Cancer Res; 2013 Oct; 19(19):5372-80. PubMed ID: 23942093
[TBL] [Abstract][Full Text] [Related]
5. Targeting Ras-Driven Cancer Cell Survival and Invasion through Selective Inhibition of DOCK1.
Tajiri H; Uruno T; Shirai T; Takaya D; Matsunaga S; Setoyama D; Watanabe M; Kukimoto-Niino M; Oisaki K; Ushijima M; Sanematsu F; Honma T; Terada T; Oki E; Shirasawa S; Maehara Y; Kang D; Côté JF; Yokoyama S; Kanai M; Fukui Y
Cell Rep; 2017 May; 19(5):969-980. PubMed ID: 28467910
[TBL] [Abstract][Full Text] [Related]
6. Synthetic lethality: A promising therapeutic strategy for hepatocellular carcinoma.
Tang L; Chen R; Xu X
Cancer Lett; 2020 Apr; 476():120-128. PubMed ID: 32070778
[TBL] [Abstract][Full Text] [Related]
7. Drug-Drug Interaction between Metformin and Sorafenib Alters Antitumor Effect in Hepatocellular Carcinoma Cells.
Harati R; Vandamme M; Blanchet B; Bardin C; Praz F; Hamoudi RA; Desbois-Mouthon C
Mol Pharmacol; 2021 Jul; 100(1):32-45. PubMed ID: 33990407
[TBL] [Abstract][Full Text] [Related]
8. TBOPP enhances the anticancer effect of cisplatin by inhibiting DOCK1 in renal cell carcinoma.
Zhang W; Zheng X; Xie S; Zhang S; Mao J; Cai Y; Lu X; Chen W; Ni H; Xie L
Mol Med Rep; 2020 Aug; 22(2):1187-1194. PubMed ID: 32626999
[TBL] [Abstract][Full Text] [Related]
9. The supression of DOCK family members by their specific inhibitors induces the cell fusion of human trophoblastic cells.
Kiyokawa E; Shoji H; Daikoku T
Biochem Biophys Res Commun; 2020 Sep; 529(4):1173-1179. PubMed ID: 32819582
[TBL] [Abstract][Full Text] [Related]
10. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
11. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
[TBL] [Abstract][Full Text] [Related]
12. CRISPR screens uncover protective effect of PSTK as a regulator of chemotherapy-induced ferroptosis in hepatocellular carcinoma.
Chen Y; Li L; Lan J; Cui Y; Rao X; Zhao J; Xing T; Ju G; Song G; Lou J; Liang J
Mol Cancer; 2022 Jan; 21(1):11. PubMed ID: 34983546
[TBL] [Abstract][Full Text] [Related]
13. Genome-Scale CRISPR screen identifies LAPTM5 driving lenvatinib resistance in hepatocellular carcinoma.
Pan J; Zhang M; Dong L; Ji S; Zhang J; Zhang S; Lin Y; Wang X; Ding Z; Qiu S; Gao D; Zhou J; Fan J; Gao Q
Autophagy; 2023 Apr; 19(4):1184-1198. PubMed ID: 36037300
[TBL] [Abstract][Full Text] [Related]
14. Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma.
Xing T; Li L; Chen Y; Ju G; Li G; Zhu X; Ren Y; Zhao J; Cheng Z; Li Y; Xu D; Liang J
Cell Rep Med; 2023 Nov; 4(11):101264. PubMed ID: 37939712
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively.
Zhou X; Li R; Jing R; Zuo B; Zheng Q
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1509-1521. PubMed ID: 32266537
[TBL] [Abstract][Full Text] [Related]
16. ATXN7L3B promotes hepatocellular carcinoma stemness and is downregulated by metformin.
Chen B; Cha JH; Yan M; Cao N; Ye P; Yan X; Yang WH
Biochem Biophys Res Commun; 2021 Oct; 573():1-8. PubMed ID: 34375763
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth.
Wang Y; Gao B; Tan PY; Handoko YA; Sekar K; Deivasigamani A; Seshachalam VP; OuYang HY; Shi M; Xie C; Goh BKP; Ooi LL; Man Hui K
FASEB J; 2019 Aug; 33(8):8759-8770. PubMed ID: 31022357
[TBL] [Abstract][Full Text] [Related]
18. Metformin Promotes 2-Deoxy-2-[
Wang Z; Kang F; Gao Y; Liu Y; Xu X; Ma X; Ma W; Yang W; Wang J
Mol Imaging Biol; 2018 Jun; 20(3):388-397. PubMed ID: 29256045
[TBL] [Abstract][Full Text] [Related]
19. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Hsieh SC; Tsai JP; Yang SF; Tang MJ; Hsieh YH
Amino Acids; 2014 Dec; 46(12):2809-22. PubMed ID: 25245054
[TBL] [Abstract][Full Text] [Related]
20. Genome-scale CRISPR activation screening identifies a role of LRP8 in Sorafenib resistance in Hepatocellular carcinoma.
Cai J; Chen J; Wu T; Cheng Z; Tian Y; Pu C; Shi W; Suo X; Wu X; Zhang K
Biochem Biophys Res Commun; 2020 Jun; 526(4):1170-1176. PubMed ID: 32312520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
